Triamcinolone acetonide acetate

Triamcinolone acetonide acetate (Triamcinolone acetonide 21-acetate) is a glucocorticoid compound and a derivative of the long-acting glucocorticoid triamcinolone acetonide; it can be used in research on skin conditions such as eczema and dermatitis.

Method: Human retinal pigment epithelial cells were treated with free Triamcinolone acetonide acetate (0.1 mg/mL) for 1, 3, and 5 days, and cell viability was assessed using the CCK-8 assay.
Result: Free Triamcinolone acetonide acetate treatment for 1–5 days decreased cell viability from 78.3% to 40.4%, demonstrating strong cytotoxicity ^[1].
Method: Human retinal pigment epithelial cells were treated with free Triamcinolone acetonide acetate (0.1 mg/mL) for 24 h, and VEGF mRNA expression levels were measured using real-time reverse transcription polymerase chain reaction (real-time RT-PCR).
Result: Compared with the control group, the free Triamcinolone acetonide acetate treatment group showed upregulation of VEGF mRNA expression ^[1].

Method: Sprague-Dawley rats were subcutaneously implanted with silicone implants loaded with Triamcinolone acetonide acetate (high-dose group: 5.2 μg/cm², low-dose group: 2.8 μg/cm²). Capsular tissues were harvested at 2, 4, 8, and 12 weeks post-implantation. Capsule thickness was measured by H&E staining, and collagen density was evaluated by Masson's trichrome staining.
Result: Compared with drug-free implants, both high- and low-dose Triamcinolone acetonide acetate groups significantly reduced capsule thickness and collagen density throughout the 12-week period (at 12 weeks, capsule thickness: drug-free group 591.0±72.4 μm, high-dose group 430.3±42.3 μm, low-dose group 379.0±40.2 μm; collagen density: drug-free group 76.8±9.8%, high-dose group 25.45±10.9%, low-dose group 30.47±5.5%), demonstrating that Triamcinolone acetonide acetate effectively inhibits peri-implant fibrosis ^[2].

DMSO: 80 mg/mL (167.88 mM), Sonication is recommended.